Abbott Vascular On Track For 60% Growth In 2007
This article was originally published in The Gray Sheet
Executive SummaryAbbott's vascular business is on target to achieve growth of "at least 60%" this year following a strong first quarter that saw continued success of the firm's Xience V everolimus-eluting coronary stent outside of the United States, the company says
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.